Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSB | P07858 | 11/20 | 0.69 |
| ▸ | CTSS | P25774 | 11/20 | 0.69 |
| ▸ | CTSL | P07711 | 2/20 | 0.45 |
| ▸ | CTSK | P43235 | 1/20 | 0.44 |
| ▸ | CTSF | Q9UBX1 | 1/20 | 0.44 |
| ▸ | TAS1R3 | Q7RTX0 | 2/20 | 0.43 |
| ▸ | TAS1R1 | Q7RTX1 | 2/20 | 0.43 |
| ▸ | PIN1 | Q13526 | 3/20 | 0.42 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.40 |
| ▸ | TACR2 | P21452 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6063679 | 0.86 | CTSB (0.50) | CTSBCTSSCTSLCTSKCTSF | |
| SCHEMBL1990971 | 0.86 | CTSS (0.54) | CTSBCTSSCTSLCTSKCTSF | |
| SCHEMBL21403460 | 0.86 | CTSS (0.54) | CTSBCTSSCTSLCTSKCTSF | |
| SCHEMBL1556742 | 0.85 | CTSS (0.65) | CTSBCTSSCTSLCTSKCTSF | |
| SCHEMBL1556740 | 0.85 | CTSS (0.65) | CTSBCTSSCTSLCTSKCTSF | |
| SCHEMBL6737504 | 0.84 | CTSL (0.63) | CTSBCTSSCTSLCTSK | |
| SCHEMBL6737501 | 0.84 | CTSL (0.63) | CTSBCTSSCTSLCTSK | |
| SCHEMBL6737536 | 0.84 | CTSB (0.54) | CTSBCTSSCTSLCTSK | |
| SCHEMBL6741538 | 0.83 | CTSB (0.46) | CTSBCTSSCTSLCTSKCTSF | |
| SCHEMBL6744795 | 0.82 | CTSL (0.57) | CTSBCTSSCTSLCTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040014796-A1 | Novel compounds and compositions as cathepsin S inhititors | AXYS PHARMACEUTICALS, INC. | 2004-01-22 | — | — | US | claimed |
| US-6492362-B1 | Compounds and compositions as cathepsin S inhibitors | AXYS PHARMACEUTICALS, INC. | 2002-12-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040014796-A1 | Novel compounds and compositions as cathepsin S inhititors | CTSS, CTSB, CTSE | CTSB 2/4885CTSS 1/4885CTSL 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.